ZITADEL
10.6.2022 11:50:09 CEST | Business Wire | Press release
ZITADEL, innovator of a transformative identity management platform, announces $2.5M in seed funding led by Nexus Venture Partners. The funding will help ZITADEL provide developers with a much-needed open-source alternative for their identity management needs and evolve its solution, scale sales growth, and nurture the open-source community. The current market landscape consists of established but closed-source players, including Auth0, Okta, Firebase, AWS Cognito, and others.
ZITADEL’s founding vision was based on the creation of a streamlined, cloud-native identity management platform to speed time-to-market for software projects. Focused on the simplicity of integration, ready-to-use self-service features, a customizable and secure login with first-class support for passwordless authentication, and an API-first strategy, ZITADEL’s unique turnkey platform offers developers unprecedented flexibility.
Developers often spend countless hours creating, configuring, and operating complex authentication and authorization systems. ZITADEL, which is built mainly in the Go programming language, solves these problems with easy-to-use integrations in multiple languages and frameworks. This flexibility enables developers to utilize prebuilt features provided by ZITADEL to dramatically improve their productivity. In addition, ZITADEL’s capabilities address existing open-source projects which were not built for a cloud-native and serverless environment.
The ZITADEL team is working towards further enriching the solution’s enterprise-readiness. New capabilities include multi-tenancy, unlimited audit trails, improved ability to self-host, and support for serverless deployments, plus the potential to extend ZITADEL’s breadth with custom code created in WebAssembly. Combined with its cloud-native architecture, ZITADEL’s self-hosting capabilities allow privacy-focused customers to own and control their data by running a dedicated version. ZITADEL’s flexible model, with its span of smart efficiency enhancements, is already the go-to solution for numerous marquee enterprise customers.
The generous free tier of ZITADEL’s cloud-hosted offering allows anybody to create a ZITADEL instance in under five minutes—without a credit card. In its ongoing commitment to deliver GDPR support to its customers, ZITADEL Cloud also provides the capability to define the country or geopolitical region in which to store their data.
“Amidst today's complex software projects, ZITADEL provides a turnkey solution that allows developers to get started easily with a secure login, user management, multi-factor authentication, social logins, authorization management, and great APIs. With ZITADEL, we provide an important component to improve the overall security of a project while reducing your time-to-market,” said ZITADEL Co-Founder and CEO, Florian Forster.
“We’re delighted to break new ground partnering with Florian and the ZITADEL team, our first-ever investment in a Swiss company. We believe the future of digital identities is passwordless. ZITADEL takes a developer-first, open-source approach to solving identity management. Its simple and easy-to-integrate building blocks help developers build secure authentication into their applications without requiring deep in-house expertise and resource commitment.” said Abhishek Sharma, Managing Director at Nexus Venture Partners. “ZITADEL is the latest addition to the Nexus family of over a dozen marquee commercial open-source companies,” added Sharma.
About ZITADEL
ZITADEL is the modern open* alternative for Auth0, Firebase Auth, and AWS Cognito, as well as Keycloak, built for the container and serverless era. It provides customers a wide range of out-of-the-box features, including secure login, self-service, OpenID Connect, OAuth2.x, SAML2, branding, Passwordless with FIDO2, OTP, U2F, and an unlimited audit trail to improve the life of developers and developers. With its legal incorporation in Switzerland, ZITADEL is in the unique position of providing its cloud services even to customers with the strictest GDPR requirements. For more information visit https://zitadel.com , follow @zitadel on Twitter, or star the repository https://github.com/zitadel/zitadel on GitHub
About Nexus Venture Partners
Nexus Venture Partners is an early-stage venture capital firm partnering with extraordinary entrepreneurs to help build product-first software companies. With $2 billion under management, Nexus operates as one team across the U.S. and India. The Nexus portfolio includes Apollo.io, Aryaka, Clover Health, Delhivery, Druva, FingerprintJS, Hasura, H2O.ai, Infra Market, Kaltura, MinIO, Observe.ai, Postman, Pubmatic, Quizizz, Rancher, Rapido, Sibros, TileDB, Turtlemint, Unacademy, WhitehatJr, and Zepto. For more information, visit www.nexusvp.com or follow @nexusvp on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005526/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom